Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioScience Health Innovations (BHIC) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for BioScience Health Innovations (BHIC) over the last 3 years, with Q3 2025 value amounting to $11.4 million.

  • BioScience Health Innovations' Shares Outstanding (Diluted Average) rose 463.56% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 463.56%. This contributed to the annual value of $42.4 million for FY2024, which is 2543.87% up from last year.
  • As of Q3 2025, BioScience Health Innovations' Shares Outstanding (Diluted Average) stood at $11.4 million, which was up 463.56% from $44.3 million recorded in Q2 2025.
  • In the past 5 years, BioScience Health Innovations' Shares Outstanding (Diluted Average) registered a high of $44.3 million during Q1 2025, and its lowest value of $10.9 million during Q3 2024.
  • In the last 3 years, BioScience Health Innovations' Shares Outstanding (Diluted Average) had a median value of $41.4 million in 2024 and averaged $34.5 million.
  • Within the past 5 years, the most significant YoY rise in BioScience Health Innovations' Shares Outstanding (Diluted Average) was 2543.87% (2024), while the steepest drop was 7300.96% (2024).
  • BioScience Health Innovations' Shares Outstanding (Diluted Average) (Quarter) stood at $33.8 million in 2023, then grew by 25.44% to $42.4 million in 2024, then crashed by 73.09% to $11.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $11.4 million in Q3 2025, compared to $44.3 million in Q2 2025 and $44.3 million in Q1 2025.